There are currently no generic Toviaz (fesoterodine) products available in the United States. The medication is under the protection of a patent that prevents any companies from manufacturing a generic version. Until this patent expires in October 2019, there will not be any generic versions of the drug available on the market.
Toviaz™ (fesoterodine fumarate) is a prescription medication used for the treatment of overactive bladder symptoms. It belongs to a group of medications known as anticholinergics. Toviaz is an extended-release medication that is taken just once a day.
Toviaz is made by Schwarz Pharma Produktions and is marketed and distributed by Pfizer, Inc. It is currently under the protection of a patent that prevents any generic Toviaz from being manufactured in the United States.
The first patent for Toviaz is set to expire in October 2019. This is the earliest predictable date that a generic version of the drug could become available. However, other circumstances could come up to extend or shorten the exclusivity period. This could include such things as other patents for specific Toviaz uses or lawsuits. Once the patent expires, several companies will likely begin manufacturing a generic version of Toviaz.
No -- fesoterodine is the active ingredient in Toviaz but is not a generic version of it. What can be confusing is that, oftentimes, the active ingredient of any drug is referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off patent, and another company besides the original manufacturer must make the product.